Paige raises additional funds for AI, cancer pathology

2019 05 08 21 57 5547 Pathology Digital Workstation 400

Artificial intelligence (AI) pathology company Paige has raised additional funding from Goldman Sachs to support its efforts related to cancer diagnostics and remote reading for pathologists.

The new, undisclosed investment adds to a previously announced $45 million in series B funding from December 2019. Paige intends to use the new influx of cash to develop diagnostic and testing products, strengthen its leadership in AI for pathologists, and develop its platform for remote viewing and routine clinical practice.

Paige also announced the addition of Goldman Sachs Managing Director David Castelblanco to its board of directors. Castelblanco has previously worked with leading cancer treatment centers as an investor and board member.

Page 1 of 7
Next Page